Watch Ticker

Gilead Sciences Inc

Go to Gilead Sciences Inc Website

$113.57

0.39 (0.34%)

Live

Previous Close

$113.18

Day Range

$113.23 - $113.9

Previous Day Range

$111.85 - $113.81

Market Cap

$140.8 billion USD

Day Vol.

1.3 million

Previous Day Vol.

5.0 million

Currency

USD

Primary Exchange

Nasdaq

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Custom Market Insights - [Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

A market research study reveals the global Lenacapavir Injection market is expected to grow to USD 5.68 Billion by 2034, with a 5.1% CAGR, driven by long-acting HIV treatment demand and innovations in injectable formulations.

Related tickers: GILD, MRK, RDY.

Read Full Article

Vandana Singh - Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales

Gilead Sciences received FDA approval for Yeztugo, a groundbreaking twice-yearly HIV prevention drug with strong clinical trial results. Analysts predict the drug could generate $6.4 billion by 2035, with Needham upgrading the stock to Buy.

Related tickers: GILD.

Read Full Article

Trending Tickers

Please sign in to view